Alexis Warren
Ophthalmology · Chicago, ILNPI 1457880171
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,295 of the $19,272 with a category attached, or 74.2%. 12 manufacturers reported payments, led by AbbVie at 58.4% of the total. 2025 is the largest year on record at $11,342, more than ten times the $335 reported in 2021. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $377.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Regeneron$4K
- Eyepoint US, Inc.$2K
- Alcon$967
- Regeneron Healthcare Solutions, Inc.$453
- Genentech USA, Inc.$396
- plus $547 from 6 others
What the payments were for
- Consulting fees$14,29574%
- Travel & lodging$7894%
- Food & beverage$4,18822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $11,253 |
| Regeneron | 4 | $3,791 |
| Eyepoint US, Inc. | 8 | $1,865 |
| Alcon | 7 | $967 |
| Regeneron Healthcare Solutions, Inc. | 4 | $453 |
| Genentech USA, Inc. | 2 | $396 |
| Alimera Sciences, Inc. | 1 | $122 |
| Bausch & Lomb Americas Inc. | 1 | $105 |
| Dutch Ophthalmic, USA | 1 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $92 |
| Biogen | 1 | $92 |
| Apellis Pharmaceuticals, Inc. | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,272 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 25 | $2,284 |
| Prednisolone Acetate | 46 | $1,908 |
| Ketorolac Tromethamine | 37 | $773 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $262 |
| Brimonidine Tartrate | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Dilraj GrewalChicago$188K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Surendra BastiChicago$126K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.